Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
Authors
Keywords
-
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-12-23
DOI
10.1007/s10557-022-07413-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis
- (2022) Nelson Wang et al. Circulation-Cardiovascular Quality and Outcomes
- Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update
- (2022) Lisa M. DeTora et al. ANNALS OF INTERNAL MEDICINE
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Epidemiology of Peripheral Artery Disease and Polyvascular Disease
- (2021) Aaron W. Aday et al. CIRCULATION RESEARCH
- Contemporary Medical Management of Peripheral Artery Disease
- (2021) Marc P. Bonaca et al. CIRCULATION RESEARCH
- LDL-Cholesterol Lowering Strategies and Population Health - Time to Move to a Cumulative Exposure Model
- (2020) Julia Brandts et al. CIRCULATION
- Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors
- (2020) Benjamin Miao et al. Journal of the American Heart Association
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease
- (2020) Lisandro D. Colantonio et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Financial Toxicity in Atherosclerotic Cardiovascular Disease in the United States: Current State and Future Directions
- (2020) Rohan Khera et al. Journal of the American Heart Association
- Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy
- (2020) E. Hope Weissler et al. ATHEROSCLEROSIS
- Using health-related quality of life to predict cardiovascular disease events
- (2019) Laura C. Pinheiro et al. QUALITY OF LIFE RESEARCH
- Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial
- (2019) J. Wouter Jukema et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Polyvascular Disease
- (2019) J. Antonio Gutierrez et al. Circulation-Cardiovascular Interventions
- Trajectories of Health-Related Quality of Life in Coronary Artery Disease
- (2018) Tolulope T. Sajobi et al.
- Trajectories of Health-Related Quality of Life in Coronary Artery Disease
- (2018) Tolulope T. Sajobi et al. Circulation-Cardiovascular Quality and Outcomes
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
- (2018) Marc P Bonaca et al. Lancet Diabetes & Endocrinology
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
- (2010) Deepak L. Bhatt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome
- (2009) Steven Yakubov CURRENT MEDICAL RESEARCH AND OPINION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started